Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program

被引：3
|
作者：
Uttervall, Katarina [1 ,2 ]
Nahi, Hareth [2 ,3 ]
Kashif, Muhammad [2 ]
Lemonakis, Konstantinos [4 ]
Rosengren, Sara [5 ]
Brolin, Janaki [6 ]
Lund, Johan [2 ,7 ]
Hansson, Markus [8 ,9 ]
机构：
[1] Karolinska Univ Hosp, Hematol Med Unit, Stockholm, Sweden
[2] Karolinska Inst, Dept Med, Stockholm, Sweden
[3] Genmab AS, Copenhagen, Denmark
[4] Skane Univ Hosp, Dept Hematol, Lund, Sweden
[5] Uppsala Univ Hosp, Dept Hematol, Uppsala, Sweden
[6] Karlstad Cent Hosp, Dept Internal Med, Karlstad, Sweden
[7] Karolinska Univ Hosp, Haematol Ctr, Stockholm, Sweden
[8] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden
[9] Univ Gothenburg, Dept Internal Med & Clin Nutr, Gothenburg, Sweden
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12605 / 12606
页数：2
相关论文
共 50 条
  • [41] Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeannene
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne
    [J]. BLOOD, 2018, 132
  • [42] REAL-WORLD BORTEZOMIB USAGE PATTERNS AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Calkins, G.
    Kohansimeh, J.
    Krishna, A.
    Green, R. J.
    Curtis, M.
    Lindberg, F. P.
    Jaskiw, A.
    Larrabee, K.
    Terry, M.
    Feinstein, R. N.
    Plotkin, L.
    Palladino, M. L.
    Nicacio, L. Viana
    [J]. HAEMATOLOGICA, 2015, 100 : 742 - 742
  • [43] Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma
    Usami, Eiseki
    Kimura, Michio
    Takenaka, Shoya
    Iwai, Mina
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (02) : 293 - 298
  • [44] Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S504
  • [45] Real-world outcomes of daratumumab monotherapy in relapsed/refractory myeloma
    Maouche, N.
    Leary, H.
    Collings, F.
    Tseu, B.
    Djebbari, F.
    Vallance, G.
    Ramasamy, K.
    Kothari, J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 125 - 125
  • [46] Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
    Delforge, Michel
    Anguille, Sebastien
    Depaus, Julien
    Meuleman, Nathalie
    De Velde, Ann Van
    Broek, Isabelle Vande
    Diels, Joris
    Erler-Yates, Nichola
    Van Causenbroeck, Sebastien
    Van Nimwegen, Kirsten
    Vandervennet, Sophie
    Lub, Susanne
    Vekemans, Marie-Christiane Madeleine
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S170 - S170
  • [47] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience
    Fucci, Ludovica
    Gensini, Lorenzo
    Coppetelli, Ugo
    La Barbera, Elettra Ortu
    Gentile, Martina
    Fiori, Luciano
    Perrone, Salvatore
    Cimino, Giuseppe
    [J]. LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [48] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Nooka, Ajay
    Chari, Ajai
    Garfall, Alfred
    Martin, Thomas
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Usmani, Saad
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
  • [49] Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
    Shragai, Tamir
    Magen, Hila
    Lavi, Noa
    Gatt, Moshe
    Trestman, Svetlana
    Zektser, Miri
    Ganzel, Chezi
    Jarchowsky, Osant
    Berger, Tamar
    Tadmor, Tamar
    Leiba, Merav
    Hertzog-Zarfaty, Katrin
    Horowitz, Netanel
    Shapira, Michael
    Varssano, David
    Berger, Yoav
    Frenkel, Shahar
    Krauthammer, Mark
    Avivi, Irit
    Luttwak, Efrat
    Cohen, Yael
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S98 - S98
  • [50] Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/ Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
    Rodriguez-Otero, Paula
    Sirvent, Maialen
    Pilar Gonzalez-Rodriguez, Ana
    Lavilla, Esperanza
    Garcia de Coca, Alfonso
    Maria Arguinano, Jose
    Marti, Josep M.
    Cabanas, Valentin
    Motllo, Cristina
    de Cabo, Erik
    Encinas, Cristina
    Murillo, Ilda
    Angel Hernandez-Rivas, Jose
    Perez-Persona, Ernesto
    Casado, Felipe
    Sampol, Antonia
    Garcia, Ricarda
    Jesus Blanchard, Maria
    Anguita, Magdalena
    Paz Lafuente, Ana
    Inigo, Belen
    Lopez, Aurelio
    Ribas, Paz
    Arnao, Mario
    Maldonado, Roberto
    Blade, Joan
    Victoria Mateos, Maria
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06): : 413 - 420
12345